Middle East Foot And Ankle Devices Market
Description
Middle East Foot And Ankle Devices Market Summary
The Middle East foot and ankle devices market size was estimated at USD 198.53 million in 2025 and is projected to reach USD 337.86 million by 2033, growing at a CAGR of 6.92% from 2026 to 2033. The Middle East is experiencing a steadily increasing burden of degenerative joint disease, and osteoarthritis has emerged as one of the most significant contributors to long-term musculoskeletal impairment in the region.
According to a ResearchGate GmbH article published in October 2025, recent epidemiological estimates indicate that the age-standardized prevalence of osteoarthritis has reached 5,342.8 cases per 100,000 population, reflecting the widespread chronic joint degeneration that has become prevalent across Middle Eastern countries. Osteoarthritis progresses, and weight-bearing joints, such as the ankle and mid-foot, are frequently affected, causing loss of mobility, pain, and instability. This rising disease burden is driving higher demand for F&A interventions ranging from joint preservation and reconstruction to orthotic support and implant-based treatments, ultimately accelerating the use of fixation devices, arthrodesis hardware, and rehabilitation products across the Middle East.
The increasing prevalence of musculoskeletal disorders largely drives the demand for devices in the Middle East. According to a Saudi Medical Journal article published in May 2024, a recent study highlights the substantial burden of musculoskeletal disorders in clinical practice. Among 11,243 patients referred for physical therapy between 2021 and 2023, 37% were diagnosed with musculoskeletal conditions, with the lower limbs significantly affected. Especially, the F&A accounted for approximately 15% of cases, underscoring the high prevalence of disorders in weight-bearing joints. This trend underscores the growing clinical need for specialized F&A interventions, including reconstructive procedures, stabilization devices, orthotic supports, and rehabilitation solutions. The data reflect an increasing demand for F&A devices across the region, driven by both degenerative conditions and trauma-related musculoskeletal impairments.
The rising burden of diabetic foot ulcers and amputations drives market growth. According to the NCBI article published in March 2025, a recent meta-analysis reviewing 17 studies in diabetes patients, 20 in diabetic foot ulcer (DFU) patients, and two in both, found that the overall pooled amputation rate among all diabetes patients is 2% (95% CI: 1%-3%), while the pooled amputation rate among DFU patients is substantially higher at 33% (range: 24%-43%). Saudi Arabia reported rates notably higher than those of other countries in the region, highlighting disparities in preventive care, patient awareness, and early intervention. These findings indicate a high clinical need for surgical implants, reconstructive devices, orthotic supports, and post-operative rehabilitation solutions to manage DFU complications and prevent amputations. Given the rising prevalence of diabetes and recurrent foot ulcers in the Middle East, demand for specialized F&A devices is expected to grow significantly, particularly in countries with higher DFU-related amputation rates.
Technological advancement drives the growth of the market. For instance, in August 2024, KFSHRC reported successful ankle-joint replacement surgeries in two patients using state-of-the-art artificial joints, along with advanced 3D imaging to precisely map joint anatomy before implantation. The use of 3D imaging has helped improve surgical precision, minimize tissue damage, shorten hospital stays, and enhance mobility outcomes. Moreover, in January 2025, HMC announced it had introduced total ankle replacement surgery in Qatar, performing TAR on multiple patients in December 2024. This marks a milestone for advanced F&A reconstructive surgery in the Gulf region, increasing access to prosthetic joints for patients with severe damage to their joints.
Middle East Foot And Ankle Devices Market Report Segmentation
This report forecasts revenue growth at the regional and country level and provides an analysis of industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the foot and ankle devices market report based on product, end use, and region:
The Middle East foot and ankle devices market size was estimated at USD 198.53 million in 2025 and is projected to reach USD 337.86 million by 2033, growing at a CAGR of 6.92% from 2026 to 2033. The Middle East is experiencing a steadily increasing burden of degenerative joint disease, and osteoarthritis has emerged as one of the most significant contributors to long-term musculoskeletal impairment in the region.
According to a ResearchGate GmbH article published in October 2025, recent epidemiological estimates indicate that the age-standardized prevalence of osteoarthritis has reached 5,342.8 cases per 100,000 population, reflecting the widespread chronic joint degeneration that has become prevalent across Middle Eastern countries. Osteoarthritis progresses, and weight-bearing joints, such as the ankle and mid-foot, are frequently affected, causing loss of mobility, pain, and instability. This rising disease burden is driving higher demand for F&A interventions ranging from joint preservation and reconstruction to orthotic support and implant-based treatments, ultimately accelerating the use of fixation devices, arthrodesis hardware, and rehabilitation products across the Middle East.
The increasing prevalence of musculoskeletal disorders largely drives the demand for devices in the Middle East. According to a Saudi Medical Journal article published in May 2024, a recent study highlights the substantial burden of musculoskeletal disorders in clinical practice. Among 11,243 patients referred for physical therapy between 2021 and 2023, 37% were diagnosed with musculoskeletal conditions, with the lower limbs significantly affected. Especially, the F&A accounted for approximately 15% of cases, underscoring the high prevalence of disorders in weight-bearing joints. This trend underscores the growing clinical need for specialized F&A interventions, including reconstructive procedures, stabilization devices, orthotic supports, and rehabilitation solutions. The data reflect an increasing demand for F&A devices across the region, driven by both degenerative conditions and trauma-related musculoskeletal impairments.
The rising burden of diabetic foot ulcers and amputations drives market growth. According to the NCBI article published in March 2025, a recent meta-analysis reviewing 17 studies in diabetes patients, 20 in diabetic foot ulcer (DFU) patients, and two in both, found that the overall pooled amputation rate among all diabetes patients is 2% (95% CI: 1%-3%), while the pooled amputation rate among DFU patients is substantially higher at 33% (range: 24%-43%). Saudi Arabia reported rates notably higher than those of other countries in the region, highlighting disparities in preventive care, patient awareness, and early intervention. These findings indicate a high clinical need for surgical implants, reconstructive devices, orthotic supports, and post-operative rehabilitation solutions to manage DFU complications and prevent amputations. Given the rising prevalence of diabetes and recurrent foot ulcers in the Middle East, demand for specialized F&A devices is expected to grow significantly, particularly in countries with higher DFU-related amputation rates.
Technological advancement drives the growth of the market. For instance, in August 2024, KFSHRC reported successful ankle-joint replacement surgeries in two patients using state-of-the-art artificial joints, along with advanced 3D imaging to precisely map joint anatomy before implantation. The use of 3D imaging has helped improve surgical precision, minimize tissue damage, shorten hospital stays, and enhance mobility outcomes. Moreover, in January 2025, HMC announced it had introduced total ankle replacement surgery in Qatar, performing TAR on multiple patients in December 2024. This marks a milestone for advanced F&A reconstructive surgery in the Gulf region, increasing access to prosthetic joints for patients with severe damage to their joints.
Middle East Foot And Ankle Devices Market Report Segmentation
This report forecasts revenue growth at the regional and country level and provides an analysis of industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the foot and ankle devices market report based on product, end use, and region:
- Product Outlook (Revenue USD Million, 2021 - 2033)
- Foot and Ankle (F&A) Trauma
- Ankle Trauma
- Fibula fixation and syndesmosis repair systems
- Talus and calcaneus trauma plates
- Pilon fracture fixation sets
- Intramedullary nails (specific to foot and ankle applications)
- Foot & Ankle (F&A) Reconstruction
- Hallux Valgus / Bunion Correction
- Hammertoe Correction
- Midfoot Reconstruction
- Hindfoot & Ankle Recon
- Total Ankle Replacement (TAR)
- Toe Joint Replacement
- Foot & Ankle (F&A) Orthobiologics
- Biologics
- Wedges
- Foot & Ankle (F&A) Soft Tissue Repair
- Lateral ligament reconstruction
- Achilles tendon repairs
- Spring ligament and deltoid repair
- Plantar plate repair systems
- Flexor/extensor tendon augmentation
- Soft tissue augmentation scaffolds
- End Use Outlook (Revenue USD Million, 2021 - 2033)
- Hospitals
- Outpatient Facilities
- Country Outlook Revenue USD Million, 2021 - 2033)
- Saudi Arabia
- UAE
- Kuwait
- Qatar
- Oman
Table of Contents
120 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Segment scope
- 1.1.2. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR’s internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. Research Assumptions
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Treatment outlook
- 2.2.2. End use outlook
- 2.3. Competitive Insights
- Chapter 3. Global Atrial Fibrillation Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Global Atrial Fibrillation: Market Analysis Tools
- 3.3.1. Industry Analysis – Porter’s
- 3.3.2. PESTLE Analysis
- 3.4. Technology Landscape
- 3.5. Case Study Analysis
- Chapter 4. Global Atrial Fibrillation Market Segment Analysis, By Treatment, 2021–2033 (USD Million)
- 4.1. Definition and Scope
- 4.2. Treatment Market Share Analysis, 2025 & 2033
- 4.3. Segment Dashboard
- 4.4. Global Atrial Fibrillation Market, by Treatment, 2021 to 2033
- 4.5. Pharmacological Treatment
- 4.5.1. Pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5.2. Anti-arrhythmic Drugs
- 4.5.2.1. Anti-arrhythmic drugs market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5.3. Anticoagulant Drugs
- 4.5.3.1. Anticoagulant drugs market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6. Non-Pharmacological Treatment
- 4.6.1. Non-pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.2. Catheter Ablation
- 4.6.2.1. Catheter ablation market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.2.2. Radiofrequency
- 4.6.2.2.1. Radiofrequency market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.2.3. HIFU
- 4.6.2.3.1. HIFU market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.2.4. Cryoablation
- 4.6.2.4.1. Cryoablation market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.2.5. Microwave
- 4.6.2.5.1. Microwave market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.2.6. Laser
- 4.6.2.6.1. Laser market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.3. Maze Surgery
- 4.6.3.1. Maze surgery market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.4. Electric Cardioversion
- 4.6.4.1. Electric cardioversion market estimates and forecasts, 2021 to 2033 (USD Million)
- Chapter 5. Global Atrial Fibrillation Market Segment Analysis, By End Use, 2021–2033 (USD Million)
- 5.1. Definition and Scope
- 5.2. End Use Market Share Analysis, 2025 & 2033
- 5.3. Segment Dashboard
- 5.4. Global Atrial Fibrillation Market, by End Use, 2021 to 2033
- 5.5. Hospitals
- 5.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.6. Specialty Clinics
- 5.6.1. Specialty Clinics market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.7. Others
- 5.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
- Chapter 6. Atrial Fibrillation Market Segment Analysis, By Region, 2021– 2033 (USD Million)
- 6.1. Regional Market Share Analysis, 2025 & 2033
- 6.2. Regional Market Dashboard
- 6.3. Regional Market Snapshot
- 6.4. Atrial Fibrillation Market Share by Region, 2025 & 2033:
- 6.5. North America
- 6.5.1. North America atrial fibrillation market, 2021 – 2033 (USD Million)
- 6.5.2. U.S.
- 6.5.2.1. Key Country Dynamics
- 6.5.2.2. Regulatory Scenario
- 6.5.2.3. Competitive Scenario
- 6.5.2.4. U.S. atrial fibrillation market, 2021 – 2033 (USD Million)
- 6.5.3. Canada
- 6.5.3.1. Key Country Dynamics
- 6.5.3.2. Regulatory Scenario
- 6.5.3.3. Competitive Scenario
- 6.5.3.4. Canada atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.5.4. Mexico
- 6.5.4.1. Key Country Dynamics
- 6.5.4.2. Regulatory Scenario
- 6.5.4.3. Competitive Scenario
- 6.5.4.4. Mexico atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.6. Europe
- 6.6.1. Europe atrial fibrillation market, 2021 – 2033 (USD Million)
- 6.6.2. UK
- 6.6.2.1. Key Country Dynamics
- 6.6.2.2. Regulatory Scenario
- 6.6.2.3. Competitive Scenario
- 6.6.2.4. UK atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.6.3. Germany
- 6.6.3.1. Key Country Dynamics
- 6.6.3.2. Regulatory Scenario
- 6.6.3.3. Competitive Scenario
- 6.6.3.4. Germany atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.6.4. France
- 6.6.4.1. Key Country Dynamics
- 6.6.4.2. Regulatory Scenario
- 6.6.4.3. Competitive Scenario
- 6.6.4.4. France atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.6.5. Italy
- 6.6.5.1. Key Country Dynamics
- 6.6.5.2. Regulatory Scenario
- 6.6.5.3. Competitive Scenario
- 6.6.5.4. Italy atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.6.6. Spain
- 6.6.6.1. Key Country Dynamics
- 6.6.6.2. Regulatory Scenario
- 6.6.6.3. Competitive Scenario
- 6.6.6.4. Spain atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.6.7. Norway
- 6.6.7.1. Key Country Dynamics
- 6.6.7.2. Regulatory Scenario
- 6.6.7.3. Competitive Scenario
- 6.6.7.4. Norway atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.6.8. Sweden
- 6.6.8.1. Key Country Dynamics
- 6.6.8.2. Regulatory Scenario
- 6.6.8.3. Competitive Scenario
- 6.6.8.4. Sweden atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.6.9. Denmark
- 6.6.9.1. Key Country Dynamics
- 6.6.9.2. Regulatory Scenario
- 6.6.9.3. Competitive Scenario
- 6.6.9.4. Denmark atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.7. Asia Pacific
- 6.7.1. Japan
- 6.7.1.1. Key Country Dynamics
- 6.7.1.2. Regulatory Scenario
- 6.7.1.3. Competitive Scenario
- 6.7.1.4. Japan atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.7.2. China
- 6.7.2.1. Key Country Dynamics
- 6.7.2.2. Regulatory Scenario
- 6.7.2.3. Competitive Scenario
- 6.7.2.4. China atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.7.3. India
- 6.7.3.1. Key Country Dynamics
- 6.7.3.2. Regulatory Scenario
- 6.7.3.3. Competitive Scenario
- 6.7.3.4. India atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.7.4. Australia
- 6.7.4.1. Key Country Dynamics
- 6.7.4.2. Regulatory Scenario
- 6.7.4.3. Competitive Scenario
- 6.7.4.4. Australia atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.7.5. South Korea
- 6.7.5.1. Key Country Dynamics
- 6.7.5.2. Regulatory Scenario
- 6.7.5.3. Competitive Scenario
- 6.7.5.4. South Korea atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.7.6. Thailand
- 6.7.6.1. Key Country Dynamics
- 6.7.6.2. Regulatory Scenario
- 6.7.6.3. Competitive Scenario
- 6.7.6.4. Thailand atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.8. Latin America
- 6.8.1. Brazil
- 6.8.1.1. Key Country Dynamics
- 6.8.1.2. Regulatory Scenario
- 6.8.1.3. Competitive Scenario
- 6.8.1.4. Brazil atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.8.2. Argentina
- 6.8.2.1. Key Country Dynamics
- 6.8.2.2. Regulatory Scenario
- 6.8.2.3. Competitive Scenario
- 6.8.2.4. Argentina atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.9. MEA
- 6.9.1. South Africa
- 6.9.1.1. Key Country Dynamics
- 6.9.1.2. Regulatory Scenario
- 6.9.1.3. Competitive Scenario
- 6.9.1.4. South Africa atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.9.2. Saudi Arabia
- 6.9.2.1. Key Country Dynamics
- 6.9.2.2. Regulatory Scenario
- 6.9.2.3. Competitive Scenario
- 6.9.2.4. Saudi Arabia atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.9.3. UAE
- 6.9.3.1. Key Country Dynamics
- 6.9.3.2. Regulatory Scenario
- 6.9.3.3. Competitive Scenario
- 6.9.3.4. UAE atrial fibrillation market, 2021 - 2033 (USD Million)
- 6.9.4. Kuwait
- 6.9.4.1. Key Country Dynamics
- 6.9.4.2. Regulatory Scenario
- 6.9.4.3. Competitive Scenario
- 6.9.4.4. Kuwait atrial fibrillation market, 2021 - 2033 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company Categorization
- 7.3. Company Profiles
- 7.3.1. AtriCure Inc.
- 7.3.1.1. Company overview
- 7.3.1.2. Financial performance
- 7.3.1.3. Product benchmarking
- 7.3.1.4. Strategic initiatives
- 7.3.2. Boehringer Ingelheim GmbH
- 7.3.2.1. Company overview
- 7.3.2.2. Financial performance
- 7.3.2.3. Product benchmarking
- 7.3.2.4. Strategic initiatives
- 7.3.3. Boston Scientific Corporation.
- 7.3.3.1. Company overview
- 7.3.3.2. Financial performance
- 7.3.3.3. Product benchmarking
- 7.3.3.4. Strategic initiatives
- 7.3.4. Bristol- Myers Squibb Corporation
- 7.3.4.1. Company overview
- 7.3.4.2. Financial performance
- 7.3.4.3. Product benchmarking
- 7.3.4.4. Strategic initiatives
- 7.3.5. Cardio Focus Inc.
- 7.3.5.1. Company overview
- 7.3.5.2. Financial performance
- 7.3.5.3. Product benchmarking
- 7.3.5.4. Strategic initiatives
- 7.3.6. Sanofi Aventis
- 7.3.6.1. Company overview
- 7.3.6.2. Financial performance
- 7.3.6.3. Product benchmarking
- 7.3.6.4. Strategic initiatives
- 7.3.7. Biosense Webster Inc.
- 7.3.7.1. Company overview
- 7.3.7.2. Financial performance
- 7.3.7.3. Product benchmarking
- 7.3.7.4. Strategic initiatives
- 7.3.8. Endoscopic Technologies Inc.
- 7.3.8.1. Company overview
- 7.3.8.2. Financial performance
- 7.3.8.3. Product benchmarking
- 7.3.8.4. Strategic initiatives
- 7.3.9. Abbott (St. Jude Medical Inc.)
- 7.3.9.1. Company overview
- 7.3.9.2. Financial performance
- 7.3.9.3. Product benchmarking
- 7.3.9.4. Strategic initiatives
- 7.3.10. Johnson & Johnson
- 7.3.10.1. Company overview
- 7.3.10.2. Financial performance
- 7.3.10.3. Product benchmarking
- 7.3.10.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



